In the quest for new vaccines, developers must balance clinical promise with practical concerns, said Kenneth Tomecki, M.D., at the 70th annual meeting of the American Academy of Dermatology. "The future for vaccines is very encouraging," says Dr. Tomecki, vice chairman, department of dermatology, Cleveland Clinic.
Social media allow for efficient networking with patients and colleagues, but using these tools successfully with patients requires setting limits and delegating authority.
The product development pipeline will deliver game-changing injectable fat treatments in the very near future, according to one dermatologist.
Although sentinel lymph node biopsy (SLNB) may be useful for staging of intermediate-thickness melanomas, says Pamela Basuk, M.D., its utility elsewhere is questionable.
Newer drugs are available to combat potentially serious infections including methicillin-resistant Staphylococcus aureus (MRSA), says Kenneth J. Tomecki, M.D., vice-chairman, department of dermatology, Cleveland Clinic. Colonization, mainly of the anterior nares, remains a major risk factor for MRSA.
As drug costs and medicolegal scrutiny increase, the future of many drugs appears murky, said Stephen E. Wolverton, M.D., at the 70th annual meeting of the American Academy of Dermatology.
Sentinel lymph node (SLN) status represents the most important prognostic factor for disease-specific survival in primary cutaneous melanomas, said Christopher K. Bichakjian, M.D., at the 70th annual meeting of the American Academy of Dermatology. However, he says, its impact on overall survival remains unclear.
"A new microwave-based device is achieving long-lasting results in treating hyperhidrosis, said Suzanne L. Kilmer, M.D., at this year's MauiDerm: Advances in Cosmetic and Medical Dermatology. Approved for primary axillary hyperhidrosis in January 2011, the miraDry System (Miramar Labs) essentially kills targeted sweat glands with microwave energy."
Treating dermatologic issues associated with pregnancy often requires individualized treatments combining various agents, an expert says.
Since there is insufficient evidence to recommend for or against prophylatic surgery for patients with congenital melanocytic nevi, physicians need to tailor management based on factors such as the size, thickness and locations of lesions for each patient, an expert says.